Objective-To investigate the effect of extended-release (ER) niacin on the metabolism of high-density lipoprotein (HDL) apolipoprotein A-I (apoA-I) in men with type 2 diabetes mellitus on a background of optimal statin therapy. Approach and Results-Twelve men with type 2 diabetes mellitus were recruited for a randomized, crossover design trial.
T ype 2 diabetes mellitus is an important risk factor for cardiovascular disease (CVD). 1, 2 Diabetic dyslipidemia plays a major role in the progression of atherosclerosis. Reduced levels of circulating high-density lipoprotein (HDL) cholesterol and its major apolipoprotein, apolipoprotein A-I (apoA-I), are particularly common in this population. 3 In type 2 diabetes mellitus, reduced levels of circulating apoA-I are likely to be a result of an increased HDL fractional catabolic rate (FCR).
Statin therapy is the cornerstone of treatment of dyslipidemia in diabetes mellitus. However, despite reaching the low-density lipoprotein (LDL) cholesterol target, only modest effects are exerted on triglyceride (TG) and HDL cholesterol, and patients often have residual CVD risk. This residual risk suggests that additional therapeutic interventions may be required to reduce CVD risk further. 4 Nicotinic acid, or niacin, is an essential B-complex vitamin (vitamin B 3 ). In pharmacological doses, it is a potent agent for raising HDL cholesterol (29%-35%) and lowering plasma TG with moderate effects on LDL cholesterol. 5, 6 Niacin has been shown to regress coronary atherosclerosis 7 and reduce the rate of coronary mortality. 8 Niacin has complex mechanisms of actions that are yet to be fully elucidated.
To address residual risk in the dyslipidemic diabetic population, the combination of statin-niacin therapy may offer potent effects in lowering plasma TG and LDL cholesterol and increasing HDL cholesterol. Data from several trials have supported the use of niacin and statins to treat dyslipidemia. [9] [10] [11] [12] [13] The combination of statin and niacin has been shown to delay the progression of atherosclerosis in individuals with known coronary heart disease. 10 Few studies have investigated the effect of niacin on lipoprotein kinetics. The results of these studies have been undertaken in small groups of subjects with inconclusive results. [14] [15] [16] [17] Despite studies on the effect of niacin on plasma lipid and lipoprotein concentrations in patients with type 2 diabetes mellitus, no studies have investigated the effects of niacin, in combination with statin, on the metabolism of lipoproteins. In the present study, we hypothesized that niacin, on a background of optimal statin therapy, would increase HDL apoA-I concentrations by reducing catabolism in patients with type 2 diabetes mellitus.
Materials and Methods
Materials and Methods are available in the online-only Supplement. Table 1 shows the clinical and biochemical characteristics of the 12 subjects with type 2 diabetes mellitus at recruitment. Table 2 shows the plasma lipid, lipoprotein, apolipoprotein, glucose, and insulin concentrations at the end of each treatment phases. Compared with rosuvastatin, the rosuvastatin plus extended-release (ER) niacin combination significantly decreased total plasma cholesterol, TG, LDL cholesterol, non-HDL cholesterol, and apolipoprotein B (all P<0.05) and significantly increased HDL cholesterol and apoA-I concentrations (P<0.001 and P<0.05, respectively). HDL cholesterol:apoA-I ratio increased significantly with ER niacin (0.77±0.02 versus 0.83±0.02; P<0.01) compared with rosuvastatin alone. TG area under the curve was significantly lower with ER niacin (39.1±4.1 versus 33.0±3.9 mmol/L.h; P=0.05); however, incremental area under the curve was not significantly different (22.9±2.2 versus 20.5±2.2 mmol/L per hour; P=0.33) with ER niacin. There was a significant increase in glucose on rosuvastatin plus ER niacin treatment. However, insulin and the Homeostasis Model of Assessment -Insulin Resistance score did not alter significantly with niacin. Cholesteryl ester transfer protein (CETP) and hepatic lipase (HL) concentrations were not significantly different between treatments.
Results
There were no significant alterations in body weight (94.4±4.8 versus 94.7±4.8 kg; P=0. 34) , systolic blood pressure (130.6±3.0 versus 131.4±3.3 mm Hg; P=0.74), diastolic blood pressure (74.6±2.2 versus 75.8±2.2 mm Hg; P=0.30), and dietary intake (7306±523 versus 7659±508 kJ/d; P=0.42) between treatments. Carryover effects were tested and found to be nonsignificant for total cholesterol, TG, LDL cholesterol, HDL cholesterol, apoB, apoA-I, insulin, and glucose.
We performed tracer metabolic studies in the nonsteady state. Patients consumed a fatty mixed meal that resulted in postprandial changes in plasma TG, HDL cholesterol, and HDL apoA-I concentrations during the first 10 hours of the metabolic study ( Figure 1 ). The dip and subsequent increase in postprandial HDL cholesterol curves mirrors the postprandial rise in TG, whereas the HDL apoA-I concentration remained, in 21 of 24 metabolic studies, constant over time. Figure 2 shows isotopic tracer curves and the model fits for HDL apoA-I after the administration of d3-leucine in a representative subject on each treatment arm. Plasma leucine tracer curves did not differ significantly between treatments. The flatter decay of the HDL apoA-I tracer curve on rosuvastatin plus niacin treatment suggests a slower catabolic rate compared with rosuvastatin alone. Table 3 shows the HDL apoA-I kinetic parameters after treatment with rosuvastatin and rosuvastatin plus ER niacin. HDL apoA-I FCR was significantly lower (P<0.005) and pool size was significantly higher (P<0.001) on rosuvastatin plus ER niacin treatment compared with rosuvastatin alone. HDL On lipid-lowering medication, n 12
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Data are mean±SD. BMI indicates body mass index; BP, blood pressure; HOMA-IR, Homeostasis Model of Assessment -Insulin Resistance; and LDL, lowdensity lipoprotein. apoA-I production rate was not altered with the addition of ER niacin (P=0. 28) .
No significant correlations were found between changes in HDL apoA-I kinetic parameters and changes in lipid concentrations. Surprisingly, change in HDL apoA-I FCR was not associated with change in plasma TG concentration (r=0.082; P=0.80), TG area under the curve (r=0.370; P=0.24), or TG incremental area under the curve (r=0.475; P=0.12).
Discussion
This is the first study to examine the effect of ER niacin, added to background statin therapy, on HDL apoA-I metabolism in patients with type 2 diabetes mellitus. We demonstrated that ER niacin significantly increases HDL cholesterol concentration and apoA-I concentration by reducing the FCR of apoA-I without significant changes to the production rate. These changes were achieved without alteration to body weight, blood pressure, and dietary intake. The effects of niacin in lowering plasma TG concentrations and elevating HDL cholesterol concentrations are consistent with the literature. 18 A previous study on the effects of niacin monotherapy (3 g/d) showed a reduction in the catabolism of HDL apoA-I in 2 normolipidemic subjects. 14 We confirm this in a population of patients with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus have elevated plasma TGs and hypercatabolism of apoA-I. The results of the present study may not extrapolate to other dyslipidemic populations. A previous study in type IV hyperlipoproteinemic subjects treated with niacin (3 g/d) also showed an increase in apoA-I concentration owing to a reduction in FCR. 18 In contrast, no differences in kinetic parameters were found in patients with type II hyperlipoproteinemia. 16 Shepherd et al 15 observed an increase in HDL apoA-I concentration in the absence of change in apoA-I FCR and production rate in 5 normolipidemic subjects. 17 More recently, Lamon-Fava et al 17 demonstrated an increased production rate of apoA-I with 2 g/d ER niacin alone and also with a lovastatin combination but no change in HDL apoA-I catabolism in subjects with combined hyperlipidemia. These findings have been summarized in the online-only Data Supplement ( Table I in the online-only Data Supplement).
These previously published studies [14] [15] [16] [17] are limited by a small sample size (n=2-6) and studied different patient populations compared with the present study. Discrepancies between the findings may be because of differences in experimental models, study design, subject characteristics, niacin dosage, and schedule and background of concomitant medication. Furthermore, differences in the methods of kinetic analysis, including use of apoA-II FCR as a measure of apoA-I catabolism, add to the heterogeneity of findings.
No significant associations were found between the changes in HDL apoA-I kinetic parameters and the changes in TG concentrations. Because TG is a strong determinant of apoA-I remodeling 19 and is associated with HDL apoA-I FCR, 20 our results imply that the effect of ER niacin on apoA-I catabolism may be independent of change in TG. However, the remodeling effect of TG on HDL cannot be completely excluded on the basis of a lack of a significant correlation. Previous studies have also failed to find associations between plasma TG and HDL apoA-I FCR. 21 rate of HDL apoA-I catabolism with ER niacin is consistent with increased HDL particle size, as suggested by the higher HDL cholesterol:apoA-I ratio ( Table 2 ). 20 Mechanistically, niacin can downregulate β-ATP synthase and prevent HDL holoparticle endocytosis. 22 The niacin receptor, GPR109A, is not involved in the effects of niacin on the hepatic catabolism of HDL apoA-I because GPR109A is not expressed in the liver. 23 Furthermore, niacin-treated Hep G2 cells exhibit a reduced uptake of HDL protein but not of HDL cholesteryl esters 24 ; thus, niacin does not act via the scavenger receptor class B type 1 pathway because this is selective to HDL cholesteryl esters. 25 The exact mechanism of niacin on HDL apoA-I catabolic pathways is yet to be completely elucidated. In terms of HDL apoA-I synthesis, niacin did not alter secretion rate, consistent with recent findings in HepG2 cells in which apoA-I gene expression was constant with niacin treatment. 26 A recent animal study demonstrated that reduced CETPmediated transfer of cholesterol from HDL to very-LDL leads to a reduced apoA-I uptake by the kidneys. 27 The study also demonstrated that HL activity was inhibited by niacin, thereby contributing to the preservation of larger HDL particles that are cleared slowly from the circulation. However, neither CETP nor HL concentrations changed significantly in the present study, a finding that is consistent with other studies. 17 No significant correlations between changes in apoA-I FCR and changes in CETP and HL were found, suggesting that changes in FCR are not CETP or HL mediated. Importantly, HL was measured as HL concentration and not as postheparin HL activity. The possible effects of niacin on the activities of these enzymes cannot be excluded. Endothelial lipase is another HDL-modifying enzyme potentially influenced by niacin.
Concern has been raised on the effect of niacin on glycemic control in patients with type 2 diabetes mellitus. Two prospective, randomized, double-blinded trials reported that the effect of niacin on glycemia was minimal in patients with stable diabetes mellitus, particularly at lower doses of niacin. 28, 29 In the current study, a significant 8% increase in glucose concentration was observed with ER niacin. This warrants the careful monitoring of glycemia to ensure that control is maintained because glycation of HDL during hyperglycemia can impair HDL functionality 30 and reduce its antiatherogenic effects, 3 in addition to other adverse effects of hyperglycemia.
Owing to the ingestion of a high-fat liquid mixed meal, a new compartmental model was developed to describe HDL apoA-I kinetics. Although a postprandial study, the plasma concentration of HDL apoA-I did not change significantly, despite changes in plasma TG and HDL cholesterol concentration. Previous HDL models were developed using data derived in the fasting state, in which a single plasma compartment and an extravascular HDL pool were sufficient to describe the tracer data. 31 In the nonfasting state, apoA-I levels are, on average, elevated compared with fasting values, 32 owing possibly to the intestinal biosynthesis of apoA-I. 33 In consideration of this, 2 biosynthesis pathways were included in the model to potentially account for the hepatic and intestinal secretion of apoA-I (Figure 3 ), analogous to the modeling concepts proposed by Fisher et al. 34 This study has limitations. Only male subjects were recruited, and given that there are differences in HDL metabolism between men and women, the results of this study may not apply to women. The sample size is small, although the current study investigated more patients than other studies investigating the effect of niacin on HDL kinetics. Further work is also required to confirm the results in other ethnic groups. Additional measurements such as CETP activity, HL activity, endothelial lipase activity, and HDL size would also be of interest.
Elevated TG and low HDL cholesterol levels are significant risk factors for coronary heart disease. 35, 36 Correcting for these residual risk factors with ER niacin therapy may provide clinical benefit, as suggested in a subgroup analysis of the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/high Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial. 37 Our study provides a kinetic explanation for the changes in lipoproteins with the addition of ER niacin to current frontline statin therapy. The results of our study indicate that in subjects with type 2 diabetes mellitus with at-target LDL cholesterol, adjunctive therapy with ER niacin increases HDL by lowering the catabolism of apoA-I. This effect was independent of changes in plasma TG with niacin treatment. Despite this, ER niacin therapy may provide CVD risk benefit to patients with type 2 diabetes mellitus by increasing HDL concentrations. Studies that investigate HDL functionality would also be important to complement this knowledge. Given that statin has a limited effect on apoA-I metabolism, combination therapy may be important in the prevention of CVD in diabetic dyslipidemia that is characterized by apoA-I hypercatabolism.
Since the early termination of the AIM-HIGH 38 and Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) 39 trials, the future use of niacin remains unclear. Careful consideration of the formulation of niacin is warranted, as is the suggestion that the time of niacin dosing (ie, mealtime versus bedtime) may affect cardiovascular outcomes. 37, 40 Finally, any cardiovascular benefit derived from niacin may be limited to patients with high TG/low HDL.
